Our study aimed to address this gap byintegrating two readily measurable biomarkers—serum albumin and blood ureanitrogen (BUN)—into a mortality prediction model for ICU-admitted AF patients.This framework not only incorporates these biochemical parameters but alsosynergizes them with established clinical covariates, which we systematicallydeveloped and rigorously validated to stratify in-hospital death risk. The gene discussed is ALB; the disease is atrial fibrillation.